S&P Futures
4,018.75 +17.50 (+0.44%) Dow Futures
32,560.00 +126.00 (+0.39%) Nasdaq Futures
12,933.50 +43.25 (+0.34%) Russell 2000 Futures
1,757.50 +9.80 (+0.56%) Crude Oil
69.56 +0.30 (+0.43%) Gold
1,977.70 -6.10 (-0.31%)
Coloplast A/S (CLPBF)
Chart Events
Performance Outlook
| Previous Close | 121.52 |
| Open | 123.25 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 123.25 - 123.25 |
| 52 Week Range | 95.75 - 159.05 |
| Volume | |
| Avg. Volume | 104 |
| Market Cap | 25.466B |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | 38.24 |
| EPS (TTM) | 3.22 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.82 (2.32%) |
| Ex-Dividend Date | Dec 02, 2022 |
| 1y Target Est | 16.50 |
- GlobeNewswire
Coloplast A/S - Allocation of Share Options
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below transactions concern allocation of share options. For further details, reference is made to Coloplast’s Remuneration Policy which was adopted in 2021. The policy is available on the group website at this
- GlobeNewswire
Coloplast launches male catheter designed to reduce the risk of urinary tract infections
Luja Coloplast's new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. Luja Coloplast's new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole. The new intermittent catheter Luja™ addresses important risk factors f
- GlobeNewswire
Coloplast A/S - Announcement no. 01/2023 – Interim Financial Report, Q1 2022/23
Q1 2022/23 Interim financial results, Q1 2022/23 1 October 2022 – 31 December 2022 Coloplast delivered a solid start to the year with 7% organic growth and a 29% EBIT margin before special items Coloplast delivered 7% organic growth in Q1. Reported revenue in DKK was up by 18%. Organic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Wound and Skin Care 1% (Wound Care -4%), and Interventional Urology 11%.Solid start in Chronic Care, with strong momentum in Ostomy Care across re
